The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Immunic Inc shares valued at $100,369 were purchased by Rudick Richard Alan on Nov 12 ’24. At $1.15 per share, Rudick Richard Alan acquired 87,300 shares. The insider’s holdings grew to 87,300 shares worth approximately $96030.00000000001 following the completion of this transaction.
As published in their initiating research note from H.C. Wainwright on November 25, 2024, Immunic Inc [IMUX] has been a Buy and the price target has been revised to $10. As of August 27, 2024, B. Riley Securities has initiated its “Buy” rating for IMUX. Earlier on October 21, 2022, SVB Leerink downgraded its rating. Their new recommendation was “a Mkt perform” for IMUX stock which previously was a “an Outperform”.
Analyzing IMUX Stock Performance
During the last five days, there has been a surge of approximately 10.00%. Over the course of the year, Immunic Inc shares have jumped approximately 10.00%. Shares of the company reached a 52-week high of $1.1500 on 01/06/25 and a 52-week low of $1.0200 on 01/02/25. A 50-day SMA is recorded $1.1492, while a 200-day SMA reached $1.3031. Nevertheless, trading volume fell to 0.55 million shares from 0.68 million shares the previous day.
Support And Resistance Levels for Immunic Inc (IMUX)
According to the 24-hour chart, there is a support level at 1.0650, which, if violated, would cause prices to drop to 1.0300. In the upper region, resistance lies at 1.1400. The next price resistance is at 1.1800. RSI (Relative Strength Index) is 48.73 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.0512, which suggests the price will decrease in the coming days. Percent R is at 31.25%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
Which companies own the most shares of Immunic Inc (IMUX)?
On September 19, 2022, H.C. Wainwright assigned a price target of “a Buy” to the stock and resumed coverage with a $26.